FibroBiologics Granted Extension by Nasdaq to Regain Compliance
MWN-AI** Summary
FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology firm distinguished by its vast portfolio of over 270 patents, has received an extension from the Nasdaq Hearings Panel to regain compliance for maintaining its listing on The Nasdaq Capital Market. This favorable determination allows the Company to work towards meeting specific financial and compliance criteria, thereby securing its listing status amidst ongoing challenges.
To remain listed, FibroBiologics must meet several conditions by set deadlines. Firstly, the Company needs to achieve an equity level of $2.5 million in accordance with Nasdaq Listing Rule 5550(b)(1) by February 27, 2026, as an alternative to the higher $35 million market value threshold under Rule 5550(b)(2). Additionally, FibroBiologics must ensure its common stock maintains a minimum bid price of $1.00 per share by April 13, 2026. Lastly, compliance with all applicable Nasdaq listing requirements must be met before the same date.
This extension offers FibroBiologics a clear path toward preserving its status on the exchange, though no immediate changes will affect the trading of the Company’s shares, which will continue under the symbol “FBLG.” The Company specializes in developing therapeutics aimed at addressing chronic diseases through innovative fibroblast and fibroblast-derived technologies.
Given the dynamic nature of biotechnology and market conditions, FibroBiologics emphasizes caution regarding forward-looking statements made in their communications, underscoring the inherent risks and uncertainties involved in their operational and financial strategies. The Company remains committed to its mission of advancing medical science through cell therapy and tissue regeneration. Further details can be accessed through the Company's website or by contacting their investor relations team.
MWN-AI** Analysis
FibroBiologics, Inc. (Nasdaq: FBLG) has received a crucial extension from the Nasdaq Hearings Panel, allowing it additional time to satisfy listing compliance requirements. This development is significant for potential investors and marks a positive step in the company's journey toward maintaining its presence on Nasdaq.
As a clinical-stage biotechnology firm focused on fibroblast therapies for chronic diseases, FibroBiologics has a substantial intellectual property portfolio, boasting over 270 patents. The nonprofit biotech sector has, in recent years, experienced substantial volatility, often driven by regulatory compliance and operational efficiency. The extension provides FibroBiologics until February 27, 2026, to meet the equity requirement of $2.5 million or the market value of $35 million, and a deadline until April 13, 2026, to achieve a minimum bid price of $1.00 per share.
This update may represent a buying opportunity for investors willing to tolerate some risk. FibroBiologics operates in a promising field—cell therapy and tissue regeneration—addressing significant healthcare challenges, such as wound healing and various chronic conditions. If the company complies with Nasdaq’s requirements, investor confidence could rebound, potentially leading to price appreciation.
Nevertheless, prospective investors should conduct due diligence, considering the company’s history of compliance challenges and the potential market risks, including liquidity concerns and R&D uncertainties. As a clinical-stage biotech firm, FibroBiologics is also subject to the unpredictable nature of clinical trials, which can significantly impact share value.
In conclusion, while the extension is favorable, it does not eliminate the inherent risks associated with investing in FibroBiologics. Investors should weigh the prospects for recovery and growth against these challenges before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it received a favorable determination from a Nasdaq Hearings Panel granting an extension to regain compliance for the continued listing of the Company’s common stock on The Nasdaq Capital Market (“Nasdaq”).
This provides FibroBiologics with a clear path to maintaining its listing on Nasdaq, subject to the Company satisfying the following conditions: meeting the equity standard of $2.5 million required under Nasdaq Listing Rule 5550(b)(1), as an alternative to the $35 million minimum Market Value of Listed Securities as set forth in Listing Rule 5550(b)(2), on or before February 27, 2026; meeting the minimum bid price requirement of $1.00 per share set forth under Nasdaq Listing Rule 5550(a)(2) on or before April 13, 2026; and compliance with all applicable criteria for continued listing on Nasdaq on or before April 13, 2026.
This determination has no immediate effect on the listing or trading of the Company's shares of common stock, which will continue to trade on Nasdaq under the symbol “FBLG.”
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
Cautionary Statement Regarding Forward-Looking Statements?
This communication?contains?"forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s intent or ability to regain compliance with the applicable Nasdaq rules and the continued trading of the Company’s shares of common stock on Nasdaq. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative?versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) FibroBiologics’ ability to?manufacture its product candidates. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether?as a result of?new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.?
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ**
What specific strategies is FibroBiologics Inc. (FBLG) implementing to meet the $2.5 million equity standard required by Nasdaq Listing Rule 5550(b)(by February 27, 2026?
How does FibroBiologics Inc. (FBLG) plan to ensure compliance with the minimum bid price requirement of $1.00 per share set by Nasdaq by the deadline of April 13, 2026?
Can FibroBiologics Inc. (FBLG) provide details on its current clinical pipeline and how it contributes to regaining Nasdaq compliance and future growth?
What risks does FibroBiologics Inc. (FBLG) foresee that could impact its ability to meet Nasdaq's compliance criteria by April 13, 2026, and how does it plan to mitigate these risks?
**MWN-AI FAQ is based on asking OpenAI questions about FibroBiologics Inc. (NASDAQ: FBLG).
NASDAQ: FBLG
FBLG Trading
-6.21% G/L:
$0.3143 Last:
604,854 Volume:
$0.34 Open:
